/TRVI
TRVI Stock - Trevi Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$11.29+0.00%
+$0.00 (+0.00%) • Jan 13
78
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.67
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.83
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+70.5%upside
Target: $19.25
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for TRVI
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$11.18 – $11.40
TARGET (TP)$19.25
STOP LOSS$10.39
RISK/REWARD1:8.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.92
52W High$14.39
52W Low$3.47
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | $-47,000 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-51,524,000 | $-33,923,000 | $-29,907,000 | $-32,476,000 | $-32,489,000 |
| Net Income | $-47,911,000 | $-29,065,000 | $-29,152,000 | $-33,940,000 | $-32,758,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-0.47 | $-0.29 | $-0.45 | $-1.49 | $-1.81 |
Company Overview
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
TRVIBeat Rate
72%
Last 18 quarters
Avg Surprise
+13.2%
EPS vs Estimate
Beats / Misses
13/5
Last 12 quarters
Latest EPS
$-0.08
Q4 2025
EPS Surprise History
Q1 24
+20.0%
$-0.08vs$-0.10
Q2 24
-22.2%
$-0.11vs$-0.09
Q3 24
-9.1%
$-0.12vs$-0.11
Q4 24
-8.3%
$-0.13vs$-0.12
Q1 25
+8.3%
$-0.11vs$-0.12
Q2 25
+30.8%
$-0.09vs$-0.13
Q3 25
+10.0%
$-0.09vs$-0.10
Q4 25
+20.0%
$-0.08vs$-0.10
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Mar 17, 2026 | $-0.10 | — | — | — |
Q4 2025 | Nov 13, 2025 | $-0.10 | $-0.08 | +20.0% | ✓ BEAT |
Q3 2025 | Aug 7, 2025 | $-0.10 | $-0.09 | +10.0% | ✓ BEAT |
Q2 2025 | May 8, 2025 | $-0.13 | $-0.09 | +30.8% | ✓ BEAT |
Q1 2025 | Mar 18, 2025 | $-0.12 | $-0.11 | +8.3% | ✓ BEAT |
Q4 2024 | Nov 6, 2024 | $-0.12 | $-0.13 | -8.3% | ✗ MISS |
Q3 2024 | Aug 8, 2024 | $-0.11 | $-0.12 | -9.1% | ✗ MISS |
Q2 2024 | May 7, 2024 | $-0.09 | $-0.11 | -22.2% | ✗ MISS |
Q1 2024 | Mar 20, 2024 | $-0.10 | $-0.08 | +20.0% | ✓ BEAT |
Q4 2023 | Nov 9, 2023 | $-0.09 | $-0.08 | +11.1% | ✓ BEAT |
Q3 2023 | Aug 10, 2023 | $-0.09 | $-0.07 | +22.2% | ✓ BEAT |
Q2 2023 | May 11, 2023 | $-0.08 | $-0.06 | +25.0% | ✓ BEAT |
Q1 2023 | Mar 16, 2023 | $-0.11 | $-0.06 | +45.5% | ✓ BEAT |
Q4 2022 | Nov 10, 2022 | $-0.15 | $-0.12 | +20.0% | ✓ BEAT |
Q3 2022 | Aug 11, 2022 | $-0.21 | $-0.14 | +33.3% | ✓ BEAT |
Q2 2022 | May 12, 2022 | $-0.31 | $-0.24 | +22.6% | ✓ BEAT |
Q1 2022 | Mar 17, 2022 | $-0.34 | $-0.28 | +17.6% | ✓ BEAT |
Q4 2021 | Nov 10, 2021 | $-0.33 | $-0.34 | -3.0% | ✗ MISS |
Q3 2021 | Aug 12, 2021 | $-0.46 | $-0.49 | -6.5% | ✗ MISS |
Latest News
Loading news...
Frequently Asked Questions about TRVI
What is TRVI's current stock price?
Trevi Therapeutics, Inc. (TRVI) is currently trading at $11.29 per share. The stock has moved +0.00% today.
What is the analyst price target for TRVI?
The average analyst price target for TRVI is $19.25, based on 1 analyst.
What sector is Trevi Therapeutics, Inc. in?
Trevi Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is TRVI's market cap?
Trevi Therapeutics, Inc. has a market capitalization of $1.45 billion, making it a small-cap company.
Does TRVI pay dividends?
No, Trevi Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorARDX
Ardelyx, Inc.
$7.04
Mkt Cap: $1.7B
NVAX
Novavax, Inc.
$8.67
Mkt Cap: $1.4B
ORIC
ORIC Pharmaceuticals, Inc.
$10.14
Mkt Cap: $1.0B
PGEN
Precigen, Inc.
$4.17
Mkt Cap: $1.3B
TERN
Terns Pharmaceuticals, Inc.
$34.45
Mkt Cap: $3.1B
TRML
Tourmaline Bio, Inc.
$47.98
Mkt Cap: $1.2B
UPB
Upstream Bio, Inc.
$32.60
Mkt Cap: $1.8B
WVE
Wave Life Sciences Ltd.
$14.22
Mkt Cap: $2.3B
ZBIO
Zenas BioPharma, Inc.
$21.57
Mkt Cap: $0.9B
ZYME
Zymeworks Inc.
$23.92
Mkt Cap: $1.8B
Explore stocks similar to TRVI for comparison